Patent & Publication

Intellectual Property (cont.)

No. Country Appl. Date Appl. No. Title Patent No
1 KR 2022-03-10 10-2022-0029918 Construction of self-circularization RNA 10-2442946
PCT 2022-03-10 PCT/KR2022/003377
JP 2022-09-09 2022-554679
CN 2022-09-22 202280003225.5
CA 2022-09-26 3,178,127
AU 2022-09-30 2022234607
EP 2022-10-04 EP22767538.6
US 2022-10-12 18/045,860 Alowance
SG 2023-07-04 11202305143S
IL 2023-07-05 304263
BR 2023-07-21 11 2023 014691 7
KR 2023-09-06 10-2023-0118503
KR 2023-09-06 10-2023-0118437
PCT 2023-09-06 PCT/KR2023/013375
PCT 2023-09-06 PCT/KR2023/013376
2 KR 2021-12-31 10-2021-0193826 TUMOR-TARGETING TRANS-SPLICING RIBOZYME EXPRESSING IMMUNE CHECKPOINT INHIBITOR AND USE THEREOF 10-2471898
PCT 2022-01-21 PCT/KR2022/0010886
CN 2023-04-21 202280007072.1
US 2023-04-28 18/034,533
JP 2023-05-22 2023-530894
CA 2023-05-29 3,203,481
AU 2023-06-07 2022210147
EP 2023-07-12 22742867.9
3 PCT 2022-01-21 PCT/KR2022/001106 CANCER THERAPEUTIC COMBINATION COMPRISING A TUMOR-TARGETING TRANS-SPLICING RIBOZYME AND AN IMMUNE CHECKPOINT INHIBITOR
4 KR 2021-07-23 10-2021-0096986 TRANS-SPLICING RIBOZYME SPECIFIC FOR RHODOPSIN TRANSCRIPT AND USES THEREOF 10-2396200
US 2021-12-30 17/646,244 11,504,388
PCT 2021-07-23 PCT/KR2021/009555
CN 2022-03-23 202180005482.8
KR 2022-03-25 10-2022-0037572 10-2522273
EP 2022-04-15 21846099.6
JP 2022-04-15 2022-522890 7334346
5 KR 2021-03-02 10-2021-0027335 APOE4 RNA TARGETING TRANS-SPLICING RIBOZYME AND USE THEREOF 10-2315736
US 2022-01-12 17/626,656
EP 2022-01-26 21760156.6
CN 2022-01-28 202180004858.3
PCT 2021-02-26 PCT/KR2021/002443
JP 2022-02-04 2022-507489
CA 2022-08-26 3,173,742
AU 2022-08-31 2021225696